• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伯氏疏螺旋体的体外抗菌药敏试验:微量稀释法测定最低抑菌浓度及时间杀菌研究

In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies.

作者信息

Dever L L, Jorgensen J H, Barbour A G

机构信息

Department of Medicine, University of Texas Health Science Center, San Antonio, Texas 78284.

出版信息

J Clin Microbiol. 1992 Oct;30(10):2692-7. doi: 10.1128/jcm.30.10.2692-2697.1992.

DOI:10.1128/jcm.30.10.2692-2697.1992
PMID:1400969
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC270500/
Abstract

The susceptibility of Borrelia burgdorferi, the causative agent of Lyme borreliosis, to various antimicrobial agents varies widely among published studies. These differences are probably due in part to variations in susceptibility testing techniques and growth endpoint determinations. We developed a microdilution method for determining the MICs of antibiotics against B. burgdorferi. The method incorporated BSK II medium, a final inoculum of 10(6) cells per ml, and a 72-h incubation period and was found to be simple and highly reproducible. A variety of antibiotics and strains of B. burgdorferi and one strain of Borrelia hermsii were examined by this method. MICs of penicillin, ceftriaxone, and erythromycin for the B31 strain of B. burgdorferi were 0.06, 0.03, and 0.03 microgram/ml, respectively. We compared the MICs obtained by the microdilution method with those obtained by a macrodilution method using similar criteria for endpoint determinations and found the values obtained by both methods to be in close agreement. To further investigate the bactericidal activities of penicillin, ceftriaxone, and erythromycin against strain B31, we used subsurface plating to determine MBCs and we also performed time-kill studies. The MBCs of penicillin, ceftriaxone, and erythromycin were 0.125, 0.03, and 0.06 micrograms/ml, respectively. Time-kill curves demonstrated a greater than or equal to 3-log10-unit killing after 72 h with penicillin, ceftriaxone, and erythromycin; ceftriaxone provided the greatest reduction in CFU. The described methods offer a more standardized and objective approach to susceptibility testing of B. burgdorferi.

摘要

莱姆病疏螺旋体病的病原体伯氏疏螺旋体对各种抗菌药物的敏感性在已发表的研究中差异很大。这些差异可能部分归因于药敏试验技术和生长终点测定的变化。我们开发了一种微量稀释法来测定抗生素对伯氏疏螺旋体的最低抑菌浓度(MIC)。该方法采用了BSK II培养基,每毫升最终接种量为10(6)个细胞,并培养72小时,结果发现该方法简单且重复性高。通过该方法检测了多种抗生素以及伯氏疏螺旋体的不同菌株和一株赫氏疏螺旋体。伯氏疏螺旋体B31菌株对青霉素、头孢曲松和红霉素的MIC分别为0.06、0.03和0.03微克/毫升。我们将微量稀释法获得的MIC与使用类似终点测定标准的常量稀释法获得的MIC进行了比较,发现两种方法获得的值非常一致。为了进一步研究青霉素、头孢曲松和红霉素对B31菌株的杀菌活性,我们使用了表面下平板接种法来测定最低杀菌浓度(MBC),并且还进行了时间-杀菌研究。青霉素、头孢曲松和红霉素的MBC分别为0.125、0.03和0.06微克/毫升。时间-杀菌曲线显示,青霉素、头孢曲松和红霉素在72小时后杀菌率大于或等于3个对数10单位;头孢曲松使菌落形成单位(CFU)减少最多。所描述的方法为伯氏疏螺旋体的药敏试验提供了一种更标准化和客观的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63ef/270500/03121662c704/jcm00034-0187-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63ef/270500/03121662c704/jcm00034-0187-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63ef/270500/03121662c704/jcm00034-0187-a.jpg

相似文献

1
In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies.伯氏疏螺旋体的体外抗菌药敏试验:微量稀释法测定最低抑菌浓度及时间杀菌研究
J Clin Microbiol. 1992 Oct;30(10):2692-7. doi: 10.1128/jcm.30.10.2692-2697.1992.
2
In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: influence of test conditions on minimal inhibitory concentration (MIC) values.
Zentralbl Bakteriol. 1995 Nov;283(1):49-60. doi: 10.1016/s0934-8840(11)80890-x.
3
In vitro activity of vancomycin against the spirochete Borrelia burgdorferi.万古霉素对螺旋体伯氏疏螺旋体的体外活性。
Antimicrob Agents Chemother. 1993 May;37(5):1115-21. doi: 10.1128/AAC.37.5.1115.
4
New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances.用于体外检测伯氏疏螺旋体对抗菌物质敏感性的新型比色微量稀释法。
Eur J Clin Microbiol Infect Dis. 2000 Jan;19(1):27-32. doi: 10.1007/s100960050005.
5
In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents.伯氏疏螺旋体对11种抗菌药物的体外敏感性
Antimicrob Agents Chemother. 1993 Jul;37(7):1444-6. doi: 10.1128/AAC.37.7.1444.
6
Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents.莱姆病螺旋体伯氏疏螺旋体对头孢呋辛及其他抗菌药物的体外和体内敏感性比较
Antimicrob Agents Chemother. 1990 Nov;34(11):2133-6. doi: 10.1128/AAC.34.11.2133.
7
In vitro activities of the everninomicin SCH 27899 and other newer antimicrobial agents against Borrelia burgdorferi.埃维霉素SCH 27899及其他新型抗菌药物对伯氏疏螺旋体的体外活性
Antimicrob Agents Chemother. 1999 Jul;43(7):1773-5. doi: 10.1128/AAC.43.7.1773.
8
In-vitro susceptibility of Borrelia burgdorferi and Borrelia hermsii to ten antimicrobial agents.
J Chemother. 1990 Dec;2(6):348-50. doi: 10.1080/1120009x.1990.11739041.
9
Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi.克拉霉素、阿奇霉素和红霉素对伯氏疏螺旋体的体外比较活性
Antimicrob Agents Chemother. 1993 Aug;37(8):1704-6. doi: 10.1128/AAC.37.8.1704.
10
In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi.氟喹诺酮类药物对疏螺旋体伯氏疏螺旋体的体外活性。
Antimicrob Agents Chemother. 2001 Sep;45(9):2486-94. doi: 10.1128/AAC.45.9.2486-2494.2001.

引用本文的文献

1
The In Vitro Antimicrobial Susceptibility of sensu lato: Shedding Light on the Known Unknowns.广义的体外抗菌药敏性:揭示已知的未知因素。
Pathogens. 2023 Sep 28;12(10):1204. doi: 10.3390/pathogens12101204.
2
Structural insights into the mechanism of overcoming Erm-mediated resistance by macrolides acting together with hygromycin-A.大环内酯类药物与潮霉素 A 协同作用克服 Erm 介导的耐药性的机制的结构见解。
Nat Commun. 2023 Jul 14;14(1):4196. doi: 10.1038/s41467-023-39653-5.
3
Endogenous Linear Plasmids lp28-4 and lp25 Are Required for Infectivity and Restriction Protection in the Lyme Disease Spirochete Borrelia mayonii.

本文引用的文献

1
Method of reliable determination of minimal lethal antibiotic concentrations.可靠测定最低致死抗生素浓度的方法。
Antimicrob Agents Chemother. 1980 Nov;18(5):699-708. doi: 10.1128/AAC.18.5.699.
2
Action of penicillin on Borrelia hermsii.青霉素对赫氏疏螺旋体的作用。
Antimicrob Agents Chemother. 1982 May;21(5):823-9. doi: 10.1128/AAC.21.5.823.
3
Lyme disease-a tick-borne spirochetosis?莱姆病——一种蜱传播的螺旋体病?
内源性线性质粒 lp28-4 和 lp25 是莱姆病螺旋体 Borrelia mayonii 感染性和限制保护所必需的。
Infect Immun. 2023 Mar 15;91(3):e0006123. doi: 10.1128/iai.00061-23. Epub 2023 Feb 28.
4
Borreliella burgdorferi Antimicrobial-Tolerant Persistence in Lyme Disease and Posttreatment Lyme Disease Syndromes.伯氏疏螺旋体在莱姆病和治疗后莱姆病综合征中的抗微生物药物耐受持久存在。
mBio. 2022 Jun 28;13(3):e0344021. doi: 10.1128/mbio.03440-21. Epub 2022 Apr 25.
5
The peptidoglycan-associated protein NapA plays an important role in the envelope integrity and in the pathogenesis of the lyme disease spirochete.肽聚糖相关蛋白 NapA 在莱姆病螺旋体的包膜完整性和发病机制中发挥重要作用。
PLoS Pathog. 2021 May 13;17(5):e1009546. doi: 10.1371/journal.ppat.1009546. eCollection 2021 May.
6
Repurposing Disulfiram (Tetraethylthiuram Disulfide) as a Potential Drug Candidate against In Vitro and In Vivo.将双硫仑(二硫化四乙秋兰姆)重新用作一种针对体外和体内情况的潜在候选药物。
Antibiotics (Basel). 2020 Sep 22;9(9):633. doi: 10.3390/antibiotics9090633.
7
Lyme Disease Frontiers: Reconciling Biology and Clinical Conundrums.莱姆病前沿:协调生物学与临床难题
Pathogens. 2019 Dec 16;8(4):299. doi: 10.3390/pathogens8040299.
8
Antimicrobial Resistance in , , and Other Rarely Investigated Veterinary and Zoonotic Pathogens.兽医和人畜共患病罕见病原体中的抗微生物药物耐药性。
Microbiol Spectr. 2018 Jul;6(4). doi: 10.1128/microbiolspec.ARBA-0029-2017.
9
Heterogeneous ceramide distributions alter spatially resolved growth of on human stratum corneum.不同的神经酰胺分布改变了人角质层上的空间分辨生长。
J R Soc Interface. 2018 Apr;15(141). doi: 10.1098/rsif.2017.0848.
10
In vitro susceptibility of Borrelia burgdorferi isolates to three antibiotics commonly used for treating equine Lyme disease.伯氏疏螺旋体分离株对三种常用于治疗马莱姆病的抗生素的体外敏感性。
BMC Vet Res. 2017 Sep 29;13(1):293. doi: 10.1186/s12917-017-1212-3.
Science. 1982 Jun 18;216(4552):1317-9. doi: 10.1126/science.7043737.
4
Antibiotic therapy in Lyme disease.莱姆病的抗生素治疗
Ann Intern Med. 1980 Jul;93(1):1-8. doi: 10.7326/0003-4819-93-1-1.
5
The spirochetal etiology of Lyme disease.莱姆病的螺旋体病因
N Engl J Med. 1983 Mar 31;308(13):733-40. doi: 10.1056/NEJM198303313081301.
6
Variation in a major surface protein of Lyme disease spirochetes.莱姆病螺旋体主要表面蛋白的变异
Infect Immun. 1984 Jul;45(1):94-100. doi: 10.1128/iai.45.1.94-100.1984.
7
Susceptibility of the Lyme disease spirochete to seven antimicrobial agents.莱姆病螺旋体对七种抗菌药物的敏感性。
Yale J Biol Med. 1984 Jul-Aug;57(4):549-53.
8
Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin.莱姆病的神经系统异常:大剂量静脉注射青霉素治疗成功
Ann Intern Med. 1983 Dec;99(6):767-72. doi: 10.7326/0003-4819-99-6-767.
9
Outbreak of tick-borne relapsing fever in Spokane County, Washington.华盛顿州斯波坎县蜱传回归热疫情
JAMA. 1969 Nov 10;210(6):1045-50.
10
Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin.假单胞菌属菌血症:庆大霉素治疗失败的药理学及其他原因
J Infect Dis. 1971 Dec;124 Suppl:S185-91. doi: 10.1093/infdis/124.supplement_1.s185.